CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,057 enrolled
Drug / intervention
Trazentadrug
Likely dose
Trazenta 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01904383
NCT01904383N/ACompleted
CompareCT.gov

Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim·observational·Posted Jul 22, 2013·Updated Oct 2, 2019

In Brief

An observational study evaluating Trazenta for Diabetes Mellitus, Type 2. Completed, enrolled 4,057 participants across 1 site.

Detailed Summary

Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
CollaboratorsEli Lilly and Company

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 22, 2013
Enrollment StartJul 1, 2013
Primary CompletionOct 4, 2018
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 12.9 years ago

Interventions

Trazentadrug

1 tablet of 5 mg Trazenta tablets once daily